<DOC>
	<DOCNO>NCT00663026</DOCNO>
	<brief_summary>The study evaluate safety effectiveness bapineuzumab treatment mild moderate Alzheimer disease . Subjects study six month receive subcutaneous injection per week .</brief_summary>
	<brief_title>Study Evaluating Bapineuzumab In Alzheimer Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable Alzheimer Disease accord National Institute Neurological Communicative Disorders Stroke/Alzheimer ` Disease Related Disorders Association ( NINCDS/ADRDA ) criteria MiniMental State Examination ( MMSE ) score 1626 Magnetic Resonance Imaging ( MRI ) show brain abnormality Other diagnose neurological psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>